Autism, Mito and Oxidative Stress
Join us for an informative discussion with Dr. Richard Frye, Director of Autism Research and Director of the Autism Multispecialty Clinic at Arkansas Children’s Hospital Research Institute.
There is increasing evidence that mitochondrial dysfunction is associated with autism spectrum disorder. Learn more about the latest research investigating the causes of this relationship, including the role of oxidative stress for these children.
Topics include:
- The evidence for mitochondrial disease and dysfunction in autism spectrum disorder
- The importance of the oxidative stress in autism spectrum disorder and its impact on mitochondrial function
- The evidence for a subset of children with autism with acquired mitochondria dysfunction as a result of high levels of oxidative stress
About The Speaker
Dr. Richard Frye is the Director of Autism Research at Arkansas Children’s Hospital Research Institute, Director of the Autism Multispecialty Clinic at Arkansas Children’s Hospital and Associate Professor in Pediatrics at the University of Arkansas for Medical Sciences. He received his MD/PhD from Georgetown University in 1998. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. Dr. Frye is a national leader in autism research. He has authored over 100 peer-reviewed publications and book chapters, and serves on several editorial boards of prestigious scientific and medical journals.
Over the past several years he has completed several clinical studies on children with autism spectrum disorder (ASD), including studies focusing on defining the clinical, behavioral, cognitive, genetic and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that address underlying physiological abnormalities in children with ASD, including open-labels on tetrahydrobiopterin, cobalamin and folinic acid and a recent double-blind placebo controlled trial on folinic acid. Future research efforts are focused on defining physiological endophenotypes of children with ASD and developing targeted treatments.
Date: 05/02/2014PDF: Click Here
Listen Now: Click Here
View Slides: Click Here